HC Wainwright & Co. Reiterates Buy on Edap TMS, Maintains $10 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Edap TMS (NASDAQ:FOCL) with a Buy and maintains $10 price target.
Read original at benzingaStocks · News reference
FocalTherics Reports Preliminary Q2 Sales Of $12.7M-$13.2M, Up 34%-39% Year-On-Year
During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements —
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 8:34 PM
- Checked
- Aug 11, 2026, 8:34 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — EDAP TMS SA (FOCL)
Filed: 2026-08-19 AccNo: 0001104659-26-098487 Size: 212 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarEdap TMS Q2 2026 Earnings Call: Complete Transcript
Edap TMS (NASDAQ:FOCL) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Read original at benzingaFocalTherics Q2 EPS $(0.38) Misses $(0.20) Estimate, Sales $13.200M Miss $14.440M Estimate
FocalTherics (NASDAQ:FOCL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.20) by 90 percent. This is a 123.53 percent decrease over losses of $(0.17) per share from the
Read original at benzinga